GHRP-6 10mg + Mod GRF 1-29 10mg

Premium GHRP-6 & Mod GRF 1-29 Blend for Sale | 10mg Each per Vial | ≥99% Purity | 48-Hour Delivery Across EU & UK

---

GHRP-6 + Mod GRF 1-29: The Synergistic Growth Hormone Secretagogue Blend for Comprehensive Research

https://eupeptidelap.co.uk/ is proud to present the GHRP-6 10mg + Mod GRF 1-29 10mg peptide blend, a premium research-grade combination of two extensively studied growth hormone secretagogues manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with this synergistic blend for sale that delivers exceptional purity, consistency, and documented quality .

This dual-peptide research blend combines GHRP-6 (Growth Hormone Releasing Peptide-6), a synthetic hexapeptide belonging to the growth hormone secretagogue receptor (GHSR) family, with Mod GRF 1-29 (also known as CJC-1295 No DAC), a synthetic analog of growth hormone-releasing hormone (GHRH) . Each vial contains 10mg of each peptide, supplied as a lyophilized solid to maintain long-term stability and integrity. HPLC-verified at ≥99% purity with full Certificates of Analysis provided, this blend is widely studied in laboratory models of growth hormone signaling, endocrine regulation, tissue repair pathways, and metabolic research .

GHRP-6 is a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that acts as a potent growth hormone secretagogue receptor agonist . Unlike other GHRPs, GHRP-6 operates through distinct intracellular signaling pathways—it stimulates GH release without increasing cAMP levels, instead activating the phosphatidylinositol (PI) second messenger system, with protein kinase C (PKC) and calcium ions playing central roles in mediating its effects . The concentrations of GHRP-6 required for half-maximal and maximal stimulation are 7 × 10⁻⁹ M and 10⁻⁷ M, respectively . This unique mechanism of action makes GHRP-6 an invaluable tool for researchers investigating alternative signaling pathways in pituitary somatotrophs.

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor 1-29) is a truncated analog of endogenous GHRH, consisting of the first 29 amino acids of the native hormone—a sequence that retains full biological activity for stimulating growth hormone release . Scientists have found that the complete biological activity of GHRH is contained in the first 29 amino acids (1-29). Research suggests that due to its potential ability to avoid metabolic clearance, Mod GRF 1-29 may be biologically more active and have a longer action duration than endogenous GHRH . The acronym “GRF 1-29” refers to this specific growth hormone releasing factor subunit, which has been extensively characterized in endocrine research .

Findings imply that Mod GRF (1-29) combined with GHRP-6 may increase growth hormone release and improve results above either peptide alone . This blend is used in preclinical research designs focused on comparative analysis of GHRHR vs. GHSR-1a receptor activation, characterization of pulsatile endocrine signaling patterns, and investigation of growth hormone axis feedback regulation .

For researchers seeking to buy peptide online EU for investigations into growth hormone dynamics, tissue regeneration, neurological function, or metabolic regulation, eupeptidelap.co.uk offers this premium blend with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.

---

The Scientific Foundation of the GHRP-6 + Mod GRF 1-29 Blend

Distinct Yet Complementary Mechanisms of Action

The GHRP-6 and Mod GRF 1-29 blend represents a strategic combination of two peptides that target distinct receptors within the growth hormone axis through different intracellular signaling pathways, potentially offering synergistic effects that surpass what either peptide might achieve alone .

Mod GRF 1-29: GHRH Receptor Activation via cAMP Pathway

Mod GRF 1-29 is designed to mimic the signaling properties of endogenous growth hormone-releasing hormone (GHRH). It selectively binds to GHRH receptors located on somatotroph cells in the anterior pituitary gland . Upon binding, it activates G-proteins associated with the inner surface of the cell membrane, leading to the production of cyclic adenosine monophosphate (cAMP) as a secondary messenger . Elevated cAMP levels activate protein kinases that phosphorylate target proteins, influencing gene expression for increased growth hormone synthesis .

One proposed pathway that Mod GRF (1-29) may activate involves the enzyme adenylyl cyclase. This enzyme is believed to convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP) . The rise in cAMP levels is thought to possibly activate protein kinase A (PKA), an enzyme that may add phosphate groups to various cellular proteins. PKA-mediated phosphorylation may modify proteins such as voltage-dependent calcium channels on the cell membrane, which might then open and stimulate secretory vesicles in pituitary cells to release growth hormones .

GHRP-6: GHSR Activation via PI/PKC Pathway

GHRP-6 operates through a fundamentally different mechanism. Studies show that GHRP-6 stimulates GH release without increasing intracellular cAMP levels, instead activating the phosphatidylinositol (PI) second messenger system . Research confirms that “the GH-stimulatory effects of GHRP-6 are obtained through activation of the PI second messenger system, and thus support earlier results that PKC and Ca2+ may play central roles in mediating the effects of GHRP-6” .

When it comes to GHRP-6, research suggests that it may bind to GHS-R1a receptors on pituitary cells and potentially induce a conformational change in these receptors and induce a nearly threefold increase in growth hormone release compared to control . This change may activate the phospholipase C (PLC) pathway, which in turn may lead to the production of secondary messengers like inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 might facilitate the release of calcium ions from intracellular stores such as the endoplasmic reticulum. This release of calcium may potentially trigger the secretion of hGH from the somatotroph cells in the anterior pituitary gland .

An antagonist for the GRF receptor, [Ac-Tyr1,D-Arg2]-GRF 1–29, significantly diminishes the effect of GHRP-2 and GRF on cAMP accumulation and GH release, but does not affect GH release induced by GHRP-6 . This confirms that GHRP-6 acts through receptors distinct from the GHRH receptor.

Synergistic Potential

The differences in how each peptide interacts with pituitary cells have led researchers to hypothesize that using both compounds simultaneously may yield synergistic actions on growth hormone secretion. Findings imply that Mod GRF (1-29) combined with GHRP-6 may increase growth hormone release and improve results above either peptide alone .

When present together at maximal concentrations, GHRP-6 and GRF produce a synergistic effect on GH release . Furthermore, combined treatment of pituitary cells with GRF and GHRP-6 results in a potentiation of the GRF-induced increase in cAMP levels, even though GHRP-6 alone has no effect on cAMP . This suggests that GHRP-6 enhances the somatotroph’s responsiveness to GHRH stimulation, likely through cross-talk between the PI/PKC and cAMP signaling pathways.

Research indicates that a GHS alone may lead to a 47-fold increase in pulsatile hGH secretion, while GHRH analogs alone might result in a 20-fold increase. Interestingly, the combination of both GHRH and GHS appears to be associated with a 54-fold increase in hGH secretion compared to controls . This finding suggests that the combination might potentially amplify hGH release more than either compound by itself, possibly due to the convergence of different signaling pathways.

---

Key Research Applications

Growth Hormone Signaling and Pituitary Research

The GHRP-6 and Mod GRF 1-29 blend is extensively used in studies investigating growth hormone dynamics, pituitary function, and endocrine regulation . The complementary mechanisms of these peptides provide researchers with a sophisticated tool for exploring:

• Receptor-Specific Signaling: Investigate how GHRH and GHSR pathways activate distinct intracellular signaling cascades (cAMP vs. PI/PKC)

• Synergistic Interactions: Study how combined receptor activation potentiates GH release beyond additive effects

• Hypothalamic-Pituitary Axis: Explore feedback mechanisms and hormonal regulation at the pituitary level

• Desensitization Studies: Basal GH release is reduced by 30% after pretreatment with GHRP-6 (10⁻⁷ M) for 1 hour, with complete reversal within 1 hour after removal of the peptide

Neuroprotection and Neurological Research

Investigations suggest that the blend of modified GRF (1-29) and GHRP-6 may be useful for mitigating the effects of mental illness and neurodegenerative diseases . The peptide blend is also being investigated for its potential to improve mood and energy levels and as an agent for clinical depression, although this research is still in progress .

Researchers speculate that GHRP-6 has been linked to enhanced learning and memory. In mouse studies, presenting GHRP-6 was associated with improved memory retention and a greater proportion of newly formed memories converted to long-term storage . There is speculation that GH analogs, like GHRP-6, may improve spatial cognition and learning .

Scientists hypothesize that improved spatial learning, problem-solving, and creative thinking are some cognitive abilities that GHRP-6 may aid in scenarios like acute stroke . Recent studies have suggested that ghrelin analogs like GHRP-6 may increase brain blood flow, minimizing infarct size and encouraging new tissue growth, potentially preventing further strokes and speeding up healing after existing strokes . Studies suggest the blend may protect brain cells from apoptosis, reduce inflammation, and delay the onset of age-related structural and functional loss in brain function .

Aging and Longevity Research

Peak levels of growth hormone occur in early development and then gradually decrease. Declining growth hormone levels are considered to directly contribute to organ decline associated with aging . Several anti-aging solutions aim to increase the body’s growth hormone supply naturally.

Investigations purport that the combination of Mod GRF (1-29) and GHRP-6 may naturally enhance growth hormone levels . The proposed capability of these peptides suggests they both may increase cellular repair, decrease cellular damage from oxidative stress, and slow telomere shortening. This potential is largely responsible for scientist theories regarding the synergistic impact of both peptides to stem age-related decline .

Wound Healing and Tissue Regeneration Research

Research suggests that tissue synthesis and wound healing appear to be improved when Mod GRF (1-29) and GHRP-6 are presented together . Researchers speculate that angiogenesis—the formation of new blood vessels—may possibly be stimulated by GHRP-6’s interaction with CD36 receptors .

Studies indicate that GHRP-6 azapeptides retain relatively high (2-27 μM) affinity for the CD36 scavenger receptor in covalent competition binding studies with the GHRP-6 prototype Hexarelin . New blood vessels that form in wounds typically speed up the healing process. Scientists hypothesize that GHRP-6 may stimulate the creation of extracellular proteins like collagen, and animal studies suggest that this may aid in wound repair .

Studies have suggested that GHRP-6 prevented myocardial injury via a decrease in reactive oxygen species and by the preservation of antioxidant defense systems, reducing free radical-mediated damage in cardiac cells based on data collected from research models .

Muscle and Bone Research

Studies suggest muscle gain may be one of the impacts of growth hormones that has received the most attention . Mod GRF (1-29) and GHRP-6 are two examples of growth hormone analogs examined for their potential to increase muscle mass by either muscular hypertrophy (enlargement of existing fibers) or muscle hyperplasia (increase in fiber number) .

Many potential effects of growth hormone analogs on bone mass appear to be mediated by IGF-1 . Studies suggest that bone-forming cells may be aided by IGF-1, encouraging their proliferation, differentiation, and survival . In addition to increasing bone mineral density, research suggests IGF-1 may also enhance bone mineralization and protect against hormone-induced bone loss, with implications for osteoporosis research .

Adipose Tissue and Metabolic Research

Research examining Mod GRF (1-29) and GHRP-6 blend suggests that both peptides might impact the distribution of adipose tissue through their impacts on growth hormone secretion . Growth hormone is thought to have lipolytic actions, especially in visceral fat areas. Growth hormone impacts adipose tissue in a depot-specific manner and influences other features of adipose tissue (for example, senescence, adipocyte subpopulations, and fibrosis), all of which might influence lipolysis . This preference may be due to a higher density of growth hormone receptors in visceral adipocytes compared to those in subcutaneous fat cell mass.

---

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources the GHRP-6 + Mod GRF 1-29 blend from certified GMP facilities with rigorous quality control protocols :

• HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography

• Mass Spectrometry Verification: Molecular weight confirmation via LC-HRMS

• Batch-Specific Certificates of Analysis: Complete documentation for each production run

• Precisely Blended: Each vial contains exactly 10mg of GHRP-6 and 10mg of Mod GRF 1-29, quality-controlled for accurate composition

Chemical and Product Specifications

Mod GRF 1-29 Specifications :

GHRP-6 Specifications :

Stability and Handling

Lyophilized Form: The peptides are supplied as a lyophilized solid to ensure long-term stability and integrity . Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide .

Storage Recommendations: Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more. However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F) .

Reconstitution: Reconstitute using bacteriostatic water or another suitable solvent according to your research protocol. Gentle swirling—not shaking—is recommended to dissolve the powder completely. Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days .

---

Real-World Research Applications and Investigator Experiences

Distinct Signaling Pathways in Pituitary Research

Researchers investigating endocrine pathways value the distinct signaling mechanisms of GHRP-6. In partially purified sheep somatotrophs, GHRP-2 and GRF increased intracellular cAMP concentrations and caused GH release in a dose-dependent manner, while GHRP-6 did not increase cAMP levels . An additive effect of maximal doses of GRF and GHRP-2 was observed in both cAMP and GH levels, whereas combined GHRP-6 and GHRP-2 at maximal doses produced an additive effect on GH release only .

The cAMP antagonist Rp-cAMP blocked GH release in response to GHRP-2 and GRF but did not prevent the effect of GHRP-6 on GH secretion . These results indicate that GHRP-6 and GHRF/GHRP-2 operate through different intracellular mechanisms, making the GHRP-6 + Mod GRF blend particularly valuable for comparative signaling studies.

Species Differences in Receptor Subtypes

An antagonist for the GRF receptor, [Ac-Tyr1,D-Arg2]-GRF 1–29, significantly diminishes the effect of GHRP-2 and GRF on cAMP accumulation and GH release, but does not affect GH release induced by GHRP-6 . This confirms that GHRP-6 acts through receptors distinct from the GHRH receptor.

Research demonstrates species differences in somatotroph response to GHRPs, likely due to different subtypes of GHRP receptor in rat versus sheep . In rat pituitary cell cultures, GHRP-6 had no effect on cAMP levels but potentiated the effect of GRF on cAMP accumulation—a synergistic effect not observed in sheep somatotrophs . These findings highlight the importance of selecting appropriate animal models for GHRP-6 research.

Desensitization and Recovery Studies

Basal GH release is reduced by 30% after pretreatment with GHRP-6 (10⁻⁷ M) for 1 hour . Pretreatment with GHRP-6 also decreases the subsequent response to GHRP-6, but not to GRF, indicating homologous desensitization . In contrast, pretreatment with GRF for 1 hour has no effect on the subsequent action of GHRP-6 or GRF on GH release . The desensitization induced by GHRP-6 is completely reversed within 1 hour after removal of the peptide, providing valuable information for designing dosing intervals in chronic studies .

CD36 Receptor Interactions

In addition to the GHS-R1a receptor, some researchers propose that GHRP-6 might also bind to other receptors, such as CD36 . CD36 receptors are found on certain immune cells, and GHRP-6’s interaction with them may impact lipid metabolism, angiogenesis, and immune regulation. In studies involving competition binding assays, researchers have suggested that GHRP-6 and oxLDL might share a common binding site on CD36. GHRP-6 may compete with oxLDL for attachment to CD36, and reducing oxLDL internalization might help lessen foam cell formation.

Key Benefits

• Premium Quality Manufacturing: GMP-certified production with rigorous quality control, ≥99% HPLC-verified purity

• Synergistic Blend: Combines GHRH analog (Mod GRF 1-29) with GHSR agonist (GHRP-6) for complementary pathway activation

• High Concentration: 10mg each per vial—ideal quantity for targeted research studies

• Distinct Signaling Pathways: GHRP-6 activates PI/PKC pathway without affecting cAMP; Mod GRF 1-29 activates cAMP pathway

• Synergistic GH Release: Combined treatment potentiates GH release up to 54-fold in research models

• Cognitive Research Applications: Investigate enhanced learning, memory retention, and spatial cognition

• Neuroprotection Studies: Research brain cell protection, reduced inflammation, and delayed age-related functional loss

• Stroke Recovery Research: Study increased brain blood flow, minimized infarct size, and new tissue growth

• Aging Research: Investigate cellular repair, oxidative stress reduction, and telomere length maintenance

• Wound Healing Studies: Research angiogenesis via CD36 receptor interaction and collagen synthesis

• Muscle Research: Study both muscular hypertrophy and hyperplasia pathways

• Bone Density Research: Investigate IGF-1 mediated osteoblast proliferation and bone mineralization

• Adipose Tissue Research: Explore depot-specific fat metabolism and lipolytic actions

• Well-Characterized Mechanism: Extensive peer-reviewed literature on receptor interactions and signaling

• Receptor Selectivity: GHRP-6 effects not blocked by GRF receptor antagonists

• Comprehensive Documentation: Certificates of Analysis with batch-specific purity data

• 48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe

• Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility

• Expert Technical Support: Knowledgeable staff for reconstitution and protocol guidance

• Secure, Discreet Packaging: Temperature-appropriate shipping containers

• EU Sourced: Manufactured and distributed from within the European Union

---

Frequently Asked Questions

Q: Is the GHRP-6 + Mod GRF 1-29 blend suitable for human consumption?

A: No. This peptide blend is strictly for research and laboratory use only . It is not for human or animal consumption, and must not be used for therapeutic, diagnostic, or clinical applications. These peptides are investigational compounds not approved by regulatory bodies like the FDA, EMA, or MHRA for any therapeutic indication; all use is considered experimental . Researchers must handle these compounds in accordance with institutional safety guidelines and local regulations.

Q: What purity level can I expect when I buy this blend from eupeptidelap.co.uk?

A: All GHRP-6 + Mod GRF 1-29 blend from eupeptidelap.co.uk is HPLC-verified at ≥99% purity . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: How should I store this peptide blend for long-term stability?

A: Store the lyophilized blend at −20°C in a dry, dark environment . Prior to reconstitution, allow the vial and solvent to reach ambient laboratory temperature. Once peptides have been received, it is imperative that they are kept cold and away from light. For longer term storage (several months to years), store peptides in a freezer at -80°C (-112°F) .

Q: What is the recommended reconstitution protocol for this blend?

A: Reconstitute using bacteriostatic water or another suitable solvent according to your research protocol . Gently swirl—do not shake—to dissolve the lyophilized powder completely. Once the peptides are reconstituted, they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days .

Q: What is the mechanism of action of GHRP-6?

A: GHRP-6 is a growth hormone secretagogue receptor (GHS-R) agonist that stimulates GH release without increasing intracellular cAMP levels . Instead, it activates the phosphatidylinositol (PI) second messenger system, with protein kinase C (PKC) and calcium ions playing central roles in mediating its effects . The concentrations of GHRP-6 required for half-maximal and maximal stimulation are 7 × 10⁻⁹ M and 10⁻⁷ M, respectively .

Q: What is the mechanism of action of Mod GRF 1-29?

A: Mod GRF 1-29 is a synthetic analog of GHRH that binds to GHRH receptors on pituitary somatotroph cells . It activates G-proteins, leading to cAMP production and protein kinase activation, which influences gene expression for GH synthesis . Due to its ability to avoid metabolic clearance, it may be biologically more active and have a longer action duration than endogenous GHRH .

Q: What research areas commonly use this peptide blend?

A: This blend is widely used in growth hormone signaling research , neuroprotection and cognitive studies , aging and longevity research , wound healing and angiogenesis investigations , muscle and bone research , adipose tissue and metabolic studies , and endocrine regulation studies .

Q: Do you ship this peptide blend to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship the GHRP-6 + Mod GRF 1-29 blend to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.

Q: What documentation do you provide with this blend orders?

A: Every order includes a Certificate of Analysis with batch-specific purity data. Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification .

Q: Why is the combination of GHRP-6 and Mod GRF 1-29 considered synergistic?

A: Findings imply that Mod GRF (1-29) combined with GHRP-6 may increase growth hormone release and improve results above either peptide alone . When present together at maximal concentrations, GHRP-6 and GRF produce a synergistic effect on GH release . Combined treatment also potentiates GRF-induced cAMP accumulation, even though GHRP-6 alone has no effect on cAMP levels . Research indicates a 54-fold increase in pulsatile hGH secretion with combined use, compared to 47-fold with GHS alone and 20-fold with GHRH analogs alone .

Q: What is the amino acid sequence of GHRP-6?

A: GHRP-6 is a hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ .

Q: What is the amino acid sequence of Mod GRF 1-29?

A: Mod GRF 1-29 has the sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ .

Q: Does GHRP-6 affect cAMP levels?

A: No. Multiple studies confirm that GHRP-6 stimulates GH release without increasing intracellular cAMP levels, distinguishing it from GHRP-2 and GRF .

Q: Does a GRF receptor antagonist block GHRP-6 effects?

A: No. An antagonist for the GRF receptor, [Ac-Tyr1,D-Arg2]-GRF 1–29, does not affect GH release induced by GHRP-6, confirming that GHRP-6 acts through receptors distinct from the GHRH receptor .

Q: Does GHRP-6 interact with receptors other than GHS-R1a?

A: Yes, research indicates that GHRP-6 may also bind to CD36 receptors, which are found on certain immune cells and may impact lipid metabolism, angiogenesis, and immune regulation .

Q: What is the EC₅₀ for GHRP-6-stimulated GH release?

A: The concentration of GHRP-6 required for half-maximal stimulation is 7 × 10⁻⁹ M (7 nM) .

Q: Do you offer bulk quantities of this peptide blend for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs. ...........................................

---

Advance Your Research with GHRP-6 + Mod GRF 1-29 Blend

eupeptidelap.co.uk is your trusted source for the GHRP-6 10mg + Mod GRF 1-29 10mg peptide blend, the premium choice for researchers investigating growth hormone dynamics, neuroprotection, tissue regeneration, and metabolic pathways. With well-characterized mechanisms, complementary receptor targeting through distinct signaling pathways, and extensive peer-reviewed literature supporting its research applications, this blend represents a sophisticated tool for exploring the complex biology of the GH axis. .  .  .  .  . .   .  .  . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 

Whether you are exploring neuroprotective effects, designing wound healing studies, investigating cognitive enhancement, or researching age-related decline, our rigorously tested blend provides the quality and consistency your work demands.

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.